SurModics (SRDX) Tops Q4 EPS by 17c; Provides Mixed Guidance

November 16, 2016 7:33 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

SurModics (NASDAQ: SRDX) reported Q4 EPS of $0.26, $0.17 better than the analyst estimate of $0.09. Revenue for the quarter came in at $18.2 million versus the consensus estimate of $16.09 million.


SurModics sees FY2017 EPS of $0.15-$0.35, versus the consensus of $1.04. SurModics sees FY2017 revenue of $63-67 million, versus the consensus of $65.3 million.

“The fourth quarter marked the continuation of the outstanding execution by the Surmodics team in fiscal 2016. I am proud of our accomplishments as we surpassed our fiscal 2016 financial goals and successfully integrated the Creagh Medical and NorMedix teams with Surmodics. We have also made significant progress on all key strategic growth priorities,” said Gary Maharaj, president and chief executive officer. “Most notably, we have frozen the design of our first 510(k) product and completed an interim look at the data from the investigational device exemption (IDE) study of our SurVeil® drug-coated balloon platform.”

For earnings history and earnings-related data on SurModics (SRDX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Management Comments

Related Entities